Avoro Capital Advisors 13F: Exits PTC Therapeutics (PTCT) Stake

Avoro Capital Advisors Exits PTC Therapeutics

Avoro Capital Advisors closed out its position in PTC Therapeutics, Inc. (NASDAQ: PTCT) during the latest reporting period. The investment manager parted with all 685,000 shares it previously held, according to a Form 13F filed with the Securities and Exchange Commission for the period ending May 15, 2026. Because 13F filings are backward-looking documents, they show a fund's holdings at the close of the quarter and may not reflect its current portfolio strategy.

Complete Position Liquidation

The transaction resulted in a 100.0% decrease in Avoro's position in PTC Therapeutics. The fund closed its position entirely, liquidating the full 685,000 shares it had owned before the quarter started.

PTC Therapeutics Stock Performance

On Sunday, shares of PTC Therapeutics were priced at $81.57. Over the last 52 weeks, the stock has traded in a range from a low of $57.74 to a high of $90.87. Its recent price action places it above its 50-day moving average of $72.19, as well as its 200-day moving average of $72.69. The company currently has a market valuation of $5.45 billion. Looking at its valuation relative to projected earnings, the stock has a forward P/E ratio of 24.38.

Recent Earnings

For its most recent financial periods, PTC Therapeutics brought in annual revenue of $1.01 billion, with revenue growth of 1.015%. The biopharmaceutical firm reported an earnings per share (EPS) of -$0.67, alongside a net margin of -0.03805. Because the company is not currently profitable, it does not have a meaningful trailing P/E ratio. Shareholders can look toward November 5, 2026, when the company is scheduled to deliver its next quarterly earnings report.

Insider Buying and Selling at PTC Therapeutics, Inc.

Several insider trades occurred in the summer of 2026. Chief Technical Operations Officer Neil Gregory Almstead was active with both stock acquisitions and sales. On June 26, 2026, Almstead exercised options to acquire 8,130 shares at $38.10 each and sold the same number of shares on the open market at an average price of $85.26, valued at $693,151.60. He also exercised options for 5,323 shares at $38.10 on June 24, 2026, selling them on the same day at an average price of $85.03 for $452,606.71. Additionally, he disposed of 23,749 shares on June 22, 2026, with no transaction value reported. The stock sales were conducted under a pre-arranged Rule 10b5-1 trading plan.

Analysts Set New Price Targets

Wall Street analysts have provided several updates on the biotechnology stock. On October 8, 2026, RBC Capital kept its Sector Perform rating on the shares and set a price target of $75.00, down from its prior target of $85.00. On September 22, 2026, Cantor Fitzgerald kept an Overweight rating and adjusted its price target to $137.00. Barclays reaffirmed an Overweight rating on August 14, 2026, with a price target of $122.00, while Wells Fargo maintained its Overweight rating on August 13, 2026, with a target of $109.00. Morgan Stanley also kept an Overweight rating on July 31, 2026, establishing a $104.00 price target. Currently, 14 analysts follow the stock, giving it a consensus buy recommendation with an average price target of $101.79.

About PTC Therapeutics

PTC Therapeutics is a biopharmaceutical company based in Warren, New Jersey. The firm focuses on discovering, developing, and commercializing treatments for rare diseases in children and adults, including Duchenne muscular dystrophy, spinal muscular atrophy, and aromatic l-amino acid decarboxylase deficiency. The company markets several therapies globally and maintains partnerships with major pharmaceutical corporations to support its drug development pipelines.

What's Ahead for PTC Therapeutics, Inc.

Market watchers will likely keep a close eye on PTC Therapeutics as its next earnings date on November 5, 2026, approaches. Future 13F filings in the coming quarters will reveal whether other institutional investors are following Avoro Capital's lead or if new funds are stepping in to build positions. These backward-looking reports offer a snapshot of institutional sentiment, but they do not serve as direct recommendations to buy or sell the stock.